JP2007533989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533989A5 JP2007533989A5 JP2007508855A JP2007508855A JP2007533989A5 JP 2007533989 A5 JP2007533989 A5 JP 2007533989A5 JP 2007508855 A JP2007508855 A JP 2007508855A JP 2007508855 A JP2007508855 A JP 2007508855A JP 2007533989 A5 JP2007533989 A5 JP 2007533989A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- amyloid beta
- group
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 6
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims 6
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108020004459 Small interfering RNA Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 108091081021 Sense strand Proteins 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125425 inverse agonist Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 229940125499 GPCR antagonist Drugs 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 230000008236 biological pathway Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940095074 cyclic amp Drugs 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000020978 protein processing Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56366104P | 2004-04-20 | 2004-04-20 | |
| US60/563,661 | 2004-04-20 | ||
| PCT/EP2005/004325 WO2005103713A2 (en) | 2004-04-20 | 2005-04-20 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007533989A JP2007533989A (ja) | 2007-11-22 |
| JP2007533989A5 true JP2007533989A5 (enExample) | 2008-06-05 |
| JP4890442B2 JP4890442B2 (ja) | 2012-03-07 |
Family
ID=35197590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508855A Expired - Fee Related JP4890442B2 (ja) | 2004-04-20 | 2005-04-20 | アミロイドベータタンパク質産生を阻害するための方法、組成物及び化合物アッセイ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7429459B2 (enExample) |
| EP (3) | EP1745295B1 (enExample) |
| JP (1) | JP4890442B2 (enExample) |
| AT (1) | ATE483981T1 (enExample) |
| CA (1) | CA2605574A1 (enExample) |
| DE (1) | DE602005023976D1 (enExample) |
| DK (1) | DK1745295T3 (enExample) |
| ES (1) | ES2353604T3 (enExample) |
| SI (1) | SI1745295T1 (enExample) |
| WO (1) | WO2005103713A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745295B1 (en) * | 2004-04-20 | 2010-10-06 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| US20100190697A1 (en) * | 2006-09-13 | 2010-07-29 | The Trustees Of Columbia University In The City If | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| GB0700645D0 (en) * | 2007-01-12 | 2007-02-21 | Eisai London Res Lab Ltd | Targets for disease therapy |
| AU2008254907A1 (en) * | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of identifying genes involved in memory formation using small interfering RNA(siRNA) |
| BRPI0811625A2 (pt) * | 2007-05-15 | 2014-11-11 | Helicon Therapeutics Inc | Métodos de tratamento de distúrbios cognitivos através da inibição da gpr12 |
| JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
| EP2440934B1 (en) | 2009-06-08 | 2014-07-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
| WO2011102901A1 (en) * | 2010-02-20 | 2011-08-25 | Ebiotec (Euroespes Biotechnology) | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate |
| US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
| US20150065376A1 (en) * | 2013-08-12 | 2015-03-05 | Holger Knaut | Expression constructs encoding g protein coupled receptors and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US5998164A (en) * | 1995-03-30 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPRZ |
| JPH11503012A (ja) * | 1995-03-30 | 1999-03-23 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ヒトｇタンパク質結合レセプター |
| US6090575A (en) * | 1995-03-30 | 2000-07-18 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPR1 |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US6420563B1 (en) | 1998-07-31 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| WO2001062765A2 (en) | 1999-02-26 | 2001-08-30 | Arena Pharmaceuticals, Inc. | Small molecule modulators of g protein-coupled receptor six |
| EP1240199A2 (en) * | 1999-12-10 | 2002-09-18 | AstraZeneca AB | Method for screening of appetite control agents |
| EP1290449A1 (en) * | 2000-05-03 | 2003-03-12 | AstraZeneca AB | Use of the g protein coupled receptor gpr3 to identify apetite control agents |
| WO2001090128A2 (en) * | 2000-05-24 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the gpr3 gene |
| US7163800B2 (en) * | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| WO2002068579A2 (en) | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| WO2003071272A1 (en) * | 2002-02-22 | 2003-08-28 | Takeda Chemical Industries, Ltd. | Method of determining ligand |
| DE60325719D1 (de) * | 2002-05-13 | 2009-02-26 | Molecular Devices Corp | Konstitutiv translozierende zelllinie |
| JP4184875B2 (ja) * | 2002-06-14 | 2008-11-19 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| US20040023380A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 6 expression |
| WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| WO2004042405A2 (en) | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3) |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| CA2539127A1 (en) * | 2003-09-19 | 2005-03-31 | Paradigm Therapeutics Limited | Receptor |
| EP1745295B1 (en) * | 2004-04-20 | 2010-10-06 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2005
- 2005-04-20 EP EP05744241A patent/EP1745295B1/en not_active Expired - Lifetime
- 2005-04-20 ES ES05744241T patent/ES2353604T3/es not_active Expired - Lifetime
- 2005-04-20 JP JP2007508855A patent/JP4890442B2/ja not_active Expired - Fee Related
- 2005-04-20 DE DE602005023976T patent/DE602005023976D1/de not_active Expired - Lifetime
- 2005-04-20 DK DK05744241.0T patent/DK1745295T3/da active
- 2005-04-20 US US11/110,274 patent/US7429459B2/en not_active Expired - Fee Related
- 2005-04-20 EP EP10174532A patent/EP2267458A3/en not_active Withdrawn
- 2005-04-20 AT AT05744241T patent/ATE483981T1/de active
- 2005-04-20 WO PCT/EP2005/004325 patent/WO2005103713A2/en not_active Ceased
- 2005-04-20 EP EP10174529A patent/EP2270513A3/en not_active Withdrawn
- 2005-04-20 CA CA002605574A patent/CA2605574A1/en not_active Abandoned
- 2005-04-20 SI SI200531166T patent/SI1745295T1/sl unknown
-
2008
- 2008-08-13 US US12/190,888 patent/US7910320B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,057 patent/US20110118338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516593A5 (enExample) | ||
| US12397065B2 (en) | Nucleic acids, peptides and methods | |
| Evert et al. | Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation | |
| Weise et al. | Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/β-catenin targets | |
| Stickeler et al. | The RNA binding protein YB‐1 binds A/C‐rich exon enhancers and stimulates splicing of the CD44 alternative exon v4 | |
| Himeda et al. | Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene | |
| US20220396604A1 (en) | Compositions comprising modified smarcb1 and uses thereof | |
| WO2013163404A1 (en) | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | |
| JP2007533989A5 (enExample) | ||
| Basu et al. | Phf21b imprints the spatiotemporal epigenetic switch essential for neural stem cell differentiation | |
| AU2023254992A1 (en) | CREBBP related cancer therapy | |
| JP2008502355A5 (enExample) | ||
| US20190338290A1 (en) | Treatment of sarcoma | |
| Yap et al. | STAT4 is a target of the hematopoietic zinc-finger transcription factor Ikaros in T cells | |
| US20240335505A1 (en) | Products and methods for promoting myogenesis | |
| Wong et al. | Rescue of tropomyosin deficiency in Drosophila and human cancer cells by synaptopodin reveals a role of tropomyosin α in RhoA stabilization | |
| Choi et al. | Repression of mRNA translation initiation by GIGYF1 via disrupting the eIF3-eIF4G1 interaction | |
| Sammons et al. | ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2 | |
| WO2011140365A1 (en) | Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid | |
| JP7776924B2 (ja) | 変異ＦＵＳの発現を選択的に抑制する修飾ｓｉＲＮＡ | |
| JP2019525903A (ja) | 転移性癌の診断及び治療の方法 | |
| CN116194138A (zh) | 治疗性靶向癌症中经由xpr1:kidins220蛋白质复合物的磷酸盐调节异常 | |
| US20110293635A1 (en) | Composition and methods for modulating toll-like receptor activity | |
| US20080008651A1 (en) | Screening Methods and Transgenic Animals for the Treatment of Beta-Globin Related Disease and Conditions | |
| US20250270530A1 (en) | Methods and compositions for endogenous exon splicing using dCas13-RBM25 fusions |